Oxford BioDynamics (LON:OBD) Shares Up 33.3% – Still a Buy?

Shares of Oxford BioDynamics Plc (LON:OBD) rose 33.3% during trading on Thursday . The company traded as high as GBX 0.14 and last traded at GBX 0.14. 29,704,521 shares traded hands during mid-day trading, an increase of 74% from the average session volume of 17,032,373 shares. The stock had previously closed at GBX 0.10.

Oxford BioDynamics Price Performance

The stock’s 50 day simple moving average is GBX 0.16 and its 200-day simple moving average is GBX 0.22. The firm has a market cap of £6.01 million, a price-to-earnings ratio of -0.70 and a beta of 0.42. The company has a debt-to-equity ratio of 131.61, a quick ratio of 2.80 and a current ratio of 2.01.

Oxford BioDynamics (LON:OBD) last announced its quarterly earnings data on Tuesday, June 30th. The biotechnology company reported GBX (0.10) earnings per share for the quarter. Oxford BioDynamics had a negative net margin of 825.61% and a negative return on equity of 451.74%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.